Oral bisphosphonate compliance and persistence: a matter of choice?

被引:0
|
作者
S. L. Silverman
J. T. Schousboe
D. T. Gold
机构
[1] Cedars-Sinai/UCLA/OMC,Department of Rheumatology
[2] Park Nicollet Medical Center,Psychiatry and Behavioral Sciences, Sociology, and Psychology and Neuroscience
[3] Duke University Medical School,undefined
来源
关键词
Osteoporosis; Medication adherence; Fractures; Bones;
D O I
暂无
中图分类号
学科分类号
摘要
Compliance to oral bisphosphonates is suboptimal, with negative consequences of increased healthcare utilization and less effective fracture risk reduction. Extending dose interval increased adherence only moderately. We used literature derived from multiple chronic conditions to examine the problem of noncompliance with osteoporosis medication. We reviewed the literature on adherence to osteoporosis medication as well as that across multiple chronic conditions to understand what is known about the cause of the poor adherence. Poor compliance to oral medications is due mostly, not to forgetfulness, but to deliberate choice. Gender differences and style of healthcare management also play a role. Preliminary data suggest psychobehavioral interventions may help to improve motivation. We need to understand better reasons for poor compliance before effective interventions can be developed. Forgetfulness is only a small part of poor compliance. Patient preferences must be considered in medication decision making.
引用
收藏
页码:21 / 26
页数:5
相关论文
共 50 条
  • [1] Oral bisphosphonate compliance and persistence: a matter of choice?
    Silverman, S. L.
    Schousboe, J. T.
    Gold, D. T.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (01) : 21 - 26
  • [2] Improving compliance and persistence with bisphosphonate therapy for osteoporosis
    Emkey, RD
    Ettinger, M
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 (04): : 18S - 24S
  • [3] Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan
    Y.-K. Soong
    K.-S. Tsai
    H.-Y. Huang
    R.-S. Yang
    J.-F. Chen
    P. C.-H. Wu
    K.-E. Huang
    Osteoporosis International, 2013, 24 : 511 - 521
  • [4] THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN TAIWAN
    Soong, Y.
    Tsai, K.
    Chen, J.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 279 - 279
  • [5] THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN TAIWAN
    Su, Y. J.
    Lin, M. J.
    Tsai, I. C.
    Soong, Y. K.
    VALUE IN HEALTH, 2010, 13 (07) : A557 - A558
  • [6] Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan
    Soong, Y. -K.
    Tsai, K. -S.
    Huang, H. -Y.
    Yang, R. -S.
    Chen, J. -F.
    Wu, P. C. -H.
    Huang, K. -E.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (02) : 511 - 521
  • [7] Low persistence with oral bisphosphonate treatment in postmenopausal osteoporosis
    Torre, C.
    Guerreiro, J.
    Mendes, Z.
    Miranda, A.
    Braganca, F.
    Cristino, J.
    Canhao, H.
    Branco, J.
    ACTA REUMATOLOGICA PORTUGUESA, 2019, 44 (02): : 114 - 125
  • [8] The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review
    Adachi, Jonathan
    Lynch, Niall
    Middelhoven, Hans
    Hunjan, Manjit
    Cowell, Warren
    BMC MUSCULOSKELETAL DISORDERS, 2007, 8 (1)
  • [9] PERSISTENCE, COMPLIANCE AND BISPHOSPHONATE SWITCHING IN PATIENTS WITH MULTIPLE MYELOMA (MM) IN GERMANY
    Intorcia, M.
    Ansorge, S.
    Giannopoulou, C.
    Hohmann, D.
    VALUE IN HEALTH, 2017, 20 (09) : A463 - A463
  • [10] Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
    Cramer, JA
    Amonkar, MM
    Hebborn, A
    Altman, R
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) : 1453 - 1460